Nurix Therapeutics’ (NRIX) “Overweight” Rating Reaffirmed at Stephens

Nurix Therapeutics (NASDAQ:NRIX)‘s stock had its “overweight” rating restated by research analysts at Stephens in a research note issued to investors on Tuesday,Benzinga reports. They currently have a $31.00 price objective on the stock. Stephens’ price target suggests a potential upside of 57.52% from the company’s previous close.

Other analysts have also issued reports about the stock. HC Wainwright raised their target price on shares of Nurix Therapeutics from $30.00 to $35.00 and gave the stock a “buy” rating in a report on Wednesday, December 11th. Needham & Company LLC reissued a “buy” rating and set a $29.00 price objective on shares of Nurix Therapeutics in a research note on Tuesday, December 10th. Jefferies Financial Group started coverage on Nurix Therapeutics in a research report on Friday, October 11th. They set a “buy” rating and a $41.00 target price on the stock. Royal Bank of Canada decreased their price target on Nurix Therapeutics from $27.00 to $26.00 and set an “outperform” rating for the company in a research report on Monday, October 14th. Finally, BTIG Research initiated coverage on Nurix Therapeutics in a report on Tuesday, December 10th. They set a “buy” rating and a $35.00 price objective on the stock. One analyst has rated the stock with a hold rating and sixteen have given a buy rating to the company. According to MarketBeat, Nurix Therapeutics presently has an average rating of “Moderate Buy” and a consensus target price of $30.35.

Nurix Therapeutics Trading Up 0.4 %

Shares of NASDAQ NRIX opened at $19.68 on Tuesday. Nurix Therapeutics has a twelve month low of $7.65 and a twelve month high of $29.56. The firm has a 50-day moving average of $20.65 and a two-hundred day moving average of $22.48. The company has a market capitalization of $1.39 billion, a price-to-earnings ratio of -6.76 and a beta of 2.14.

Insider Activity at Nurix Therapeutics

In other news, CFO Houte Hans Van sold 3,546 shares of the firm’s stock in a transaction dated Friday, November 1st. The stock was sold at an average price of $24.28, for a total transaction of $86,096.88. Following the completion of the sale, the chief financial officer now directly owns 33,724 shares of the company’s stock, valued at $818,818.72. This trade represents a 9.51 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Gwenn Hansen sold 3,437 shares of the business’s stock in a transaction that occurred on Wednesday, October 30th. The shares were sold at an average price of $24.30, for a total value of $83,519.10. Following the completion of the sale, the insider now directly owns 50,670 shares of the company’s stock, valued at approximately $1,231,281. The trade was a 6.35 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 9,351 shares of company stock valued at $227,158. Insiders own 9.80% of the company’s stock.

Institutional Investors Weigh In On Nurix Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the business. Amalgamated Bank increased its position in Nurix Therapeutics by 30.6% during the third quarter. Amalgamated Bank now owns 2,182 shares of the company’s stock worth $49,000 after buying an additional 511 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its stake in shares of Nurix Therapeutics by 31.6% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,330 shares of the company’s stock worth $54,000 after acquiring an additional 559 shares in the last quarter. Quest Partners LLC increased its holdings in shares of Nurix Therapeutics by 21.3% during the 3rd quarter. Quest Partners LLC now owns 7,458 shares of the company’s stock valued at $168,000 after acquiring an additional 1,312 shares during the last quarter. Teachers Retirement System of The State of Kentucky raised its stake in shares of Nurix Therapeutics by 8.4% in the 3rd quarter. Teachers Retirement System of The State of Kentucky now owns 30,024 shares of the company’s stock valued at $675,000 after acquiring an additional 2,329 shares in the last quarter. Finally, Quarry LP lifted its holdings in Nurix Therapeutics by 3,746.2% in the 3rd quarter. Quarry LP now owns 2,500 shares of the company’s stock worth $56,000 after purchasing an additional 2,435 shares during the last quarter.

Nurix Therapeutics Company Profile

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.